Evidence by cancer type
Metronomic therapy in prostate cancer
90 studies and 8 trials indexed. 1 trial is recruiting or about to start.
Compiled automatically by Metronomic.com from PubMed and ClinicalTrials.gov. Automated listing. Each item links to its original source. Last refresh: Nov 15, 2026
Titles appear as published. A listing is not an endorsement, and a single study rarely settles a question. Not medically reviewed. Educational information, not medical advice.
Trials recruiting or starting soon
- RecruitingPhase 2ChinaNCT06854250Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate CancerSun Yat-sen University
See all 8 trials for prostate cancer in the trial finder
Newest studies
- StudyProstate2026 OctEvaluation of [(225)Ac]Ac-PSMA-617 vis-a-vis Rechallenge [(177)Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.Agrawal R, et al.
- StudyOncologist2026 Apr 10Impact of geriatric covariates on metronomic cyclophosphamide efficacy and tolerance-the CHEMETROLD study.Griffe C, et al.
- Case reportCase Rep Oncol2026 Jan-DecNovel Combination of Metronomic Cyclophosphamide and Darolutamide Induces Sustained Clinical Response in Heavily Treated Prostate Cancer with Prostate-Specific Membrane Antigen-Negative Liver Metastases and Rapid Disease Progression.Patel VM, et al.
- StudySci Rep2025 Feb 3Personalized metronomic radiopharmaceutical therapy through injection profile optimization via physiologically based pharmacokinetic (PBPK) modeling.Golzaryan A, et al.
- ReviewCancer Lett2024 Aug 28"Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities".Delahousse J, et al.
- CommentaryAsian J Surg2024 AugEfficacy and safety of metronomic cyclophosphamide combined with abiraterone and dexamethasone in heavily pretreated metastatic castration-resistant prostate cancer: A retrospective, real-world study.Zhang L, et al.
- StudyClin Genitourin Cancer2024 AprTherapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC).Mar N, et al.
- StudyJ Cancer Res Clin Oncol2024 Feb 8Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer.Peres T, et al.
- StudyCancer Res Commun2023 JulMetronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers.Mitra Ghosh T, et al.
- StudyBMC Cancer2023 Apr 4Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer.Asowed M, et al.
- Clinical trialESMO Open2022 DecMOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors.Vicier C, et al.
- ReviewWorld J Clin Oncol2022 Aug 24Potential of mRNA vaccines to become versatile cancer vaccines.Tsao SY
- StudyFuture Oncol2022 JunCytoreductive prostate cryoablation and metronomic cyclophosphamide for metastatic hormone-sensitive prostate cancer.Li Y, et al.
- ReviewJ Clin Med2022 May 18Metronomic Chemotherapy in Prostate Cancer.Wysocki PJ, et al.
- ReviewJ Clin Med2022 May 15Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review.Parshad S, et al.
- StudyFront Pharmacol2021Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer.Mitra Ghosh T, et al.
- StudyCancers (Basel)2021 Jul 12Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer.Bamodu OA, et al.
- StudyVaccines (Basel)2021 Mar 8Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy.Merlano MC, et al.
- StudyStem Cells2020 Sep 27CD44(+) cells determine fenofibrate-induced microevolution of drug-resistance in prostate cancer cell populations.Wróbel T, et al.
- StudyInt J Cancer2020 Aug 15Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer.Laheurte C, et al.
- StudyMed Oncol2019 Aug 9Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs.Calvani N, et al.
- StudyFuture Oncol2019 AprActivity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer.Caffo O, et al.
- Case reportClin Genitourin Cancer2019 AprMetronomic Oral Cyclophosphamide in 2 Heavily Pretreated Patients With Metastatic Castration-resistant Prostate Cancer With Homologous Recombination Deficiency (HRD): A Case Report.Ling HH and Lin YC
- StudyUrologe A2019 Apr[Metronomic chemotherapy with oral cyclophosphamide : An individual option for the metastatic castration-resistant prostate cancer patient?].Knipper S, et al.
- StudyCancers (Basel)2019 Jan 11Fenofibrate Augments the Sensitivity of Drug-Resistant Prostate Cancer Cells to Docetaxel.Luty M, et al.
- StudyProstate2018 SepCabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.Jarvis C, et al.
- StudyActa Oncol2018 JulCastration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate cancer.Jellvert Å, et al.
- StudyIndian J Cancer2018 Jan-MarMetronomic therapy in metastatic castrate-resistant prostate cancer: Experience from a tertiary cancer care center.Dabkara D, et al.
- StudyJ Rural Med2017 NovFeasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer.Kubota H, et al.
- StudyAsia Pac J Clin Oncol2017 JunEfficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer.Jeong Y and Lee JL
- Clinical trialInvest New Drugs2016 DecClinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.Di Desidero T, et al.
- StudyJ Clin Diagn Res2016 NovMetronomic Chemotherapy: Seems Prowess to Battle against Cancer in Current Scenario.Muthusamy P, et al.
- Clinical trialMed Oncol2016 AugMetronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.Calcagno F, et al.
- StudyProstate Int2016 MarChemotherapy in frail elderly patients with hormone-refractory prostate cancer: A "real world" experience.Tralongo P, et al.
- Randomized trialCancer Immunol Immunother2016 FebA randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.Noguchi M, et al.
- StudyCancer Microenviron2015 AugAnakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia.Hart C, et al.
- Clinical trialOncotarget2015 Jul 20Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.Podrazil M, et al.
- StudyOncotarget2015 Jun 30Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.Chi KH, et al.
- Clinical trialClin Exp Metastasis2015 FebLenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.Wang J, et al.
- StudyMed Oncol2015 JanMetronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.Barroso-Sousa R, et al.
